Actively Recruiting
A Study to Evaluate ALN-4285 in Adult Healthy Volunteers
Led by Alnylam Pharmaceuticals · Updated on 2026-05-14
76
Participants Needed
1
Research Sites
66 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to: * evaluate the safety and tolerability of single ascending doses of ALN-4285 in healthy volunteers * characterize the single-dose pharmacokinetics (PK) of ALN-4285
CONDITIONS
Official Title
A Study to Evaluate ALN-4285 in Adult Healthy Volunteers
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Has a body mass index (BMI) of 6gt;=18.0 kg/m�5E2 and 6lt;=30 kg/m�5E2
- Has 12-lead ECG within normal limits or with no clinically significant abnormalities in the opinion of the Investigator
You will not qualify if you...
- Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) 6gt;upper limit of normal (ULN)
- Has total bilirubin 6gt;ULN
- Has systolic blood pressure 6gt;140 mmHg and/or a diastolic blood pressure 6gt;90 mmHg
- Has an estimated glomerular filtration (eGFR) of 6lt;90 mL/min/1.73m�5E2 at screening
- Has received an investigational agent within the last 30 days or 5 half-lives
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Clinical Trial Site
London, United Kingdom, NW10 7EW
Actively Recruiting
Research Team
C
Clinical Trial Information Line
CONTACT
C
Clinical Trial Information Line
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here